Dermatology Debates: The Derms on Drugs Try to Change Minds
Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!
--------
44:24
--------
44:24
Serious Medical Derm: Hot Topics & Clinical Controversies—Derms on Drugs Style
Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.We break down the newest literature and answer:Does immunotherapy really help with high-risk squamous cell carcinoma?Are pemphigus patients getting more rituximab than they need?Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?Is the Mind.Px test actually helpful for picking a psoriasis biologic?What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?Which treatment factors predict scabies cure?Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!Hit play and stay on the cutting edge of medical dermatology!1. Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma2. Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial3. Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium4. Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis5. Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes6. Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab7. Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure
--------
46:14
--------
46:14
Chronic Spontaneous Urticaria: New Trials, Hot Treatments, and Patient Pearls with Dr. Jason Hawkes
Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.We’re joined by CSU expert Dr. Jason Hawkes to discuss:-How Dupixent is changing the game for CSU and why dermatologists are leading the charge-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients-How we explain to CSU patients that they don’t need allergy testing!-Clinical pearls for work-up, navigating treatment guidelines, safety, and accessPerfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.Hit play and stay ahead on the cutting edge of CSU care!1. Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound2. Remibrutinib in Chronic Spontaneous Urticaria3. Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials
--------
54:57
--------
54:57
The Cutting Edge of Dermatology: New Data, Hot Topics, and Clinical Pearls
Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.This week, we break down:Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitisThe future of autoimmune disease treatment: genetically modified T cellsWhat policies people actually support (and will pay for) to reduce skin cancer ratesJAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch forThe latest on rising contact allergens: which ones are on the move and whyPacked with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.Don’t miss out—hit play for your weekly dose of dermatology insights!For links to all articles visit ScholarsinMedicine.com1. Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study2. Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid3. Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry4. Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study5. Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents6. Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries7. North American Contact Dermatitis Group Patch Test Results: 2021–2022
--------
54:01
--------
54:01
Alopecia, Alopecia and More Alopecia: Practical Tips for Dermatology Providers with Dr. Michelle Tarbox
Ever feel overwhelmed by the flood of alopecia treatments and supplements?Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.In this episode, we tackle:Which labs to order for telogen effluviumWhich hair loss supplements are actually worth recommendingThe truth about red light helmetsHow and when to use prescription therapies for hair lossCan shampoo really help with alopecia?Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.Listen now for all the answers—and maybe a few laughs!
Derms on Drugs is where cutting-edge dermatology meets mediocre comedy. Each week three dermatologists – Matt Zirwas, Laura Ferris and Tim Patton – discuss, debate, and dissect the hottest topics in dermatology.
It's everything you need to know to be on the cutting-edge of dermatology and it’ll be the most fun you’ve ever had while actually learning something useful.
Derms on Drugs is produced by Scholars in Medicine, an online educational platform (scholarsinmedicine.com) exclusively for healthcare professionals of all levels of experience and education.
USA